You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》美銀證券上調泰格醫藥(03347.HK)目標價至150元 評級「買入」
阿思達克 11-02 12:03
美銀證券發表報告指,泰格醫藥(03347.HK)今年第三季業績表現顯示,對比上半年受疫情影響,CRO(臨床合同研究機構)的活動有所復甦,集團第三季銷售按年增22%,經營盈利亦按年升37%至2.52億元人民幣,優於該行預期7%。

該行表示,在需求強勁的環境下,加上整合兩個較高毛利的業務,泰格的定價能力繼續改善,集團的經營毛利率有驚喜,達29.7%。

美銀上調泰格醫藥股份目標價,由126元升至150元,評級維持「買入」,並調升集團今年至2022年盈利預測分別5%至7%,以反映更高的毛利率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account